Please login to the form below

Not currently logged in
Email:
Password:

cenegermin

This page shows the latest cenegermin news and features for those working in and with pharma, biotech and healthcare.

European Commission approves Dompé’s orphan drug

European Commission approves Dompé’s orphan drug

Oxervate will treat patients with neurotrophic keratitis. Italian biopharmaceutical company Dompé has received the go-ahead for Oxervate (cenegermin) for the treatment of moderate-to-severe neurotrophic keratitis (NK), a rare ... Researchers found that

Latest news

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
OPEN Health

OPEN Health brings together deep scientific knowledge, global understanding, and broad specialist expertise to support our clients in improving health...

Latest intelligence

Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
...
How to pick the perfect training program for your healthcare professionals
You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...